Results 151 to 160 of about 2,475,393 (270)

A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors. [PDF]

Front Immunol, 2019
Izumi K, Nishie W, Beniko M, Shimizu H.
europepmc   +1 more source

Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells

, 2012
—The purpose of this study was to investigate the role of dipeptidyl peptidase IV in regulating the effects of 2 of its substrates, neuropeptide Y1-36 and peptide YY1-36, on proliferation of and collagen production by preglomerular vascular smooth muscle
Stanton J. Kochanek, Edwin K. Jackson, Delbert G. Gillespie   +2 more
core  

Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Incretin effect helps in regulating glucose homeostasis and maintaining glycaemic control within the human body. This effect is achieved by the two naturally occurring incretin hormones: glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1).
Nora H. J. Alharbi
wiley   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, Volume 53, Issue 10, Page 1429-1438, October 2026.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. [PDF]

J Clin Med, 2018
Kim YG, Jeon JY, Kim HJ, Kim DJ, Lee KW, Moon SY, Han SJ.   +6 more
europepmc   +1 more source

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9403-9411, October 2026.
ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii, Valerio Velardi, Christian Marinelli, Antonino Lax, Matteo Monami, Edoardo Mannucci   +5 more
wiley   +1 more source

Discovery of bioactive peptides from <i>Arbacia lixula</i> as dipeptidyl peptidase-IV inhibitors: An <i>in silico</i> approach. [PDF]

J Adv Pharm Technol Res
Taufiqa Z, Maisa BA, Cuandra KN, Sihombing EF, Ridho MF, Silalahi SPDE, Widi VSN, Adila AR, Quinneala AZ, Indrajaya AH, Febriani R, Hasna ZRA, Rahmadani S, Kurniasari E, Lubis MM, Hastuti AP.   +15 more
europepmc   +1 more source

In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies. [PDF]

In Silico Pharmacol, 2017
Sharma MC, Jain S, Sharma R.
europepmc   +1 more source

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9346-9355, October 2026.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind, Viktor Rotbain Curovic, Martin Bæk Blond, Hiddo J. L. Heerspink, Tine Willum Hansen, Frederik Persson, Karolina Sulek, Cristina Legido‐Quigley, Peter Rossing   +10 more
wiley   +1 more source

Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. [PDF]

Curr Ther Res Clin Exp
Tuersun A, Mohetaer M, Hou G, Cheng G.
europepmc   +1 more source